Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 65
Filter
Add more filters










Publication year range
1.
Eur J Pharm Biopharm ; 131: 224-231, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30149060

ABSTRACT

Antisolvent precipitation of poorly water-soluble drugs is a promising formulation technique to synthesize amorphous nanoparticles. The dissolution behavior of these nanoparticles is improved because of the high specific surface area and the amorphous state, leading to an enhanced bioavailability of the drug molecules. Nevertheless, stabilization of precipitated drug nanoparticles against agglomeration and recrystallization, which constitutes a key issue for further processing steps, has turned out to be a major challenge. For that reason, the present study presents a synthesis method to produce long-term stable amorphous ibuprofen nanoparticles via antisolvent precipitation. To reach this goal, a new precipitation method was developed: antisolvent melt precipitation (AMP). Formulation strategies (e.g. varying fraction of stabilizer) as well as process parameters (e.g. temperature) were under study to estimate their influence on particle size, size distribution, crystallinity, morphology and stability of synthesized drug nanoparticles.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/chemistry , Ibuprofen/chemistry , Algorithms , Crystallization , Drug Compounding , Drug Stability , Nanoparticles , Particle Size , Solubility , Solvents , Temperature
2.
Mol Pharm ; 12(1): 34-45, 2015 Jan 05.
Article in English | MEDLINE | ID: mdl-25412253

ABSTRACT

UNLABELLED: In vitro studies of ocular bioavailability of active pharmaceutical ingredients (API) from colloidal drug delivery systems do not consider physiological shear stress generated by eyelid wiping and tear flow. The present study introduces a live cell imaging approach which enables the investigation of model drug uptake from various formulations under shear stress by using custom-made microchannels for the cultivation of human corneal epithelial cells (HCE-T). Coumarin-6 (C-6) was used as a model API incorporated into solid lipid nanoparticles and liposomes, and as an aqueous crystalline suspension. Confocal laser scanning microscopy visualized C-6 uptake into HCE-T cells in a time-resolved manner with an applied shear stress of 0.1 Pa. Static conditions were also studied for comparative purposes. Additionally, solid lipid nanoparticles (SLN) were labeled with a fluorescent phospholipid to check whether C-6 uptake was associated with SLN incorporation into the cells. RESULTS: Intact SLN were not incorporated into the cells, i.e., C-6 was passively redistributed from SLN to lipophilic cellular compartments. C-6 was enriched up to a given limit in HCE-T cells within 5 min of contact with the dispersions both under static and under flow conditions. The C-6 delivery rate from liposomes was superior to that from SLN whereby the suspension exhibited the lowest rate. C-6 release rates were comparable for static and flow conditions. Alternate flushing with formulations and buffer revealed that cells accumulated C-6. The results suggest that combining microfluidics with live cell imaging provides a valuable option for in vitro studies of ocular drug delivery.


Subject(s)
Cornea/drug effects , Coumarins/chemistry , Epithelial Cells/drug effects , Nanoparticles/chemistry , Thiazoles/chemistry , Biological Availability , Cell Line , Cell Line, Tumor , Cell Survival , Cornea/metabolism , Crystallization , Drug Delivery Systems , Drug Design , Epithelial Cells/cytology , Eye/drug effects , Fluorometry/methods , Humans , Lipids/chemistry , Liposomes/chemistry , Liposomes/metabolism , Micelles , Microfluidic Analytical Techniques , Microfluidics , Microscopy, Confocal , Microscopy, Electron, Transmission , Microscopy, Fluorescence
3.
Int J Pharm ; 476(1-2): 41-9, 2014 Dec 10.
Article in English | MEDLINE | ID: mdl-25261709

ABSTRACT

For the development of any colloidal system, thorough characterization is extremely essential. This article discusses the physicochemical characterization of sildenafil-loaded solid lipid nanoparticle dispersions (SLN) including stability analysis over 6 months time period for possible pulmonary administration for the treatment of pulmonary arterial hypertension (PAH). SLN consisting of phospholipid and triglycerides were manufactured using a novel microchannel homogenization method. These sildenafil-loaded SLN were then subjected to physicochemical characterization namely, particle size and distribution over shelf life, differential scanning calorimetry (DSC), wide angle X-ray diffraction (WAXD) and analysis of nebulization performance of these SLN by the means of next generation impactor (NGI). Additionally, the morphology of nebulized particles was assessed by transmission electron microscopy using negative staining technique. The solubility of sildenafil citrate and base in the lipid matrix was determined and was 0.1% w/w and 1% w/w, respectively. From the particle size measurements, it was observed that SLN without sildenafil demonstrated consistent particle sizes over 6 months. For the sildenafil-loaded SLN, increased particle sizes were found after manufacturing and further increased within weeks. From WAXD studies, after 6 months high intensity reflections corresponding to the stable ß modification were observed. From DSC results, the peak minimum temperatures increased upon storage, hinting at a transformation to the stable ß modification of triglycerides in the case of sildenafil-loaded SLN. Hence, it can be concluded that even small drug concentration influences particle size and stability.


Subject(s)
Lipids/chemistry , Nanoparticles , Phosphodiesterase 5 Inhibitors/chemistry , Piperazines/administration & dosage , Sulfonamides/administration & dosage , Calorimetry, Differential Scanning , Chemistry, Pharmaceutical/methods , Drug Carriers/chemistry , Drug Stability , Drug Storage , Lung/metabolism , Microscopy, Electron, Transmission , Particle Size , Phospholipids/chemistry , Piperazines/chemistry , Purines/administration & dosage , Purines/chemistry , Sildenafil Citrate , Solubility , Sulfonamides/chemistry , Triglycerides/chemistry , X-Ray Diffraction
4.
Inhal Toxicol ; 25(9): 536-43, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23905970

ABSTRACT

The aim of this study was to investigate the potential cytotoxicity of solid lipid nanoparticles (SLN) loaded with sildenafil. The SLNs were tested as a new drug delivery system (DDS) for the inhalable treatment of pulmonary hypertension in human lungs. Solubility of sildenafil in SLN lipid matrix (30:70 phospholipid:triglyceride) was determined to 1% sildenafil base and 0.1% sildenafil citrate, respectively. Sildenafil-loaded SLN with particle size of approximately 180 nm and monomodal particle size distribution were successfully manufactured using a novel microchannel homogenization method and were stable up to three months. Sildenafil-loaded SLN were then used in in vitro and ex vivo models representing lung and heart tissue. For in vitro models, human alveolar epithelial cell line (A459) and mouse heart endothelium cell line (MHEC5-T) were used. For ex vivo models, rat precision cut lung slices (PCLS) and rat heart slices (PCHS) were used. All the models were treated with plain SLN and sildenafil-loaded SLN in a concentration range of 0-5000 µg/ml of lipid matrix. The toxicity was evaluated in vitro and ex vivo by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Median lethal dose 50% (LD50) values for A549 cells and PCLS were found to be in the range of 1200-1900 µg/ml while for MHEC5-T cells and precision cut heart slices values were found between 1500 and 2800 µg/ml. PCHS showed slightly higher LD50 values in comparison to PCLS. Considering the toxicological aspects, sildenafil-loaded SLN could have potential in the treatment of pulmonary hypertension via inhalation route.


Subject(s)
Drug Carriers/toxicity , Nanoparticles/toxicity , Phosphodiesterase 5 Inhibitors/toxicity , Piperazines/toxicity , Sulfones/toxicity , Animals , Cell Line , Cell Line, Tumor , Cell Survival/drug effects , Drug Carriers/chemistry , Female , Humans , In Vitro Techniques , Lung/drug effects , Lung/pathology , Mice , Myocardium/pathology , Nanoparticles/chemistry , Phosphatidylcholines/chemistry , Phosphodiesterase 5 Inhibitors/chemistry , Piperazines/chemistry , Purines/chemistry , Purines/toxicity , Rats , Rats, Wistar , Sildenafil Citrate , Solubility , Sulfones/chemistry , Triglycerides/chemistry
5.
Oncogene ; 32(33): 3829-39, 2013 Aug 15.
Article in English | MEDLINE | ID: mdl-22964639

ABSTRACT

We report on the role of hexamethylene-bis-acetamide-inducible protein 1 (HEXIM1) as an inhibitor of metastasis. HEXIM1 expression is decreased in human metastatic breast cancers when compared with matched primary breast tumors. Similarly we observed decreased expression of HEXIM1 in lung metastasis when compared with primary mammary tumors in a mouse model of metastatic breast cancer, the polyoma middle T antigen (PyMT) transgenic mouse. Re-expression of HEXIM1 (through transgene expression or localized delivery of a small molecule inducer of HEXIM1 expression, hexamethylene-bis-acetamide) in PyMT mice resulted in inhibition of metastasis to the lung. Our present studies indicate that HEXIM1 downregulation of HIF(-)1α protein allows not only for inhibition of vascular endothelial growth factor-regulated angiogenesis, but also for inhibition of compensatory pro-angiogenic pathways and recruitment of bone marrow-derived cells (BMDCs). Another novel finding is that HEXIM1 inhibits cell migration and invasion that can be partly attributed to decreased membrane localization of the 67 kDa laminin receptor, 67LR, and inhibition of the functional interaction of 67LR with laminin. Thus, HEXIM1 re-expression in breast cancer has therapeutic advantages by simultaneously targeting more than one pathway involved in angiogenesis and metastasis. Our results also support the potential for HEXIM1 to indirectly act on multiple cell types to suppress metastatic cancer.


Subject(s)
Mammary Neoplasms, Experimental/metabolism , Neovascularization, Pathologic/metabolism , Transcription Factors/metabolism , Animals , Blotting, Western , Chromatography, High Pressure Liquid , Female , Flow Cytometry , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Immunohistochemistry , Immunoprecipitation , Lung Neoplasms/metabolism , Lung Neoplasms/secondary , MCF-7 Cells , Mammary Neoplasms, Experimental/pathology , Mice , Mice, Transgenic , Neoplasm Invasiveness/pathology , Oligonucleotide Array Sequence Analysis , RNA-Binding Proteins , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Tandem Mass Spectrometry , Tissue Array Analysis , Two-Hybrid System Techniques
7.
Crit Rev Immunol ; 21(1-3): 215-48, 2001.
Article in English | MEDLINE | ID: mdl-11642606

ABSTRACT

The T cells of many cancer patients are naturally sensitized to tumor-associated antigens (Ag), or they can readily be sensitized with vaccine maneuvers. In melanoma patients, the adoptive transfer of such T cells can often be causally linked to the objective regression of established tumors. So far, few patients have shown sustained clinical benefit from such therapy, but preclinical mouse studies have now clearly delineated the hurdles that must be overcome to render T-cell-based antitumor therapy effective. Contrary to earlier expectations, it is now established that remarkably potent CD4+ and CD8+ pre-effector T cells are naturally sensitized even in mice bearing progressive, weakly immunogenic tumors. However, such T cells often display signal transduction impairments as a consequence of the tumor environment, which limit their acquisition of optimal effector function. Extracorporealization and culture of these tumor-sensitized T cells with appropriate activation stimuli not only restores normal signal transduction, but also confers resolute effector activity that can often sustain tumor rejection upon reinfusion. In mouse studies, the L-selectin(low) fraction of T cells in tumor-draining lymph nodes (TDLN) constitutes the potent pre-effector population and comprises both CD4+ and helper-independent CD8+ T cells. Appropriate in vitro activation confers an apparently unrestricted trafficking capacity to this fraction, and even the ability to proliferate within the tumor bed, leading to unprecedented tumor rejection at anatomic sites (e.g., subcutaneous and intracranial) that were historically refractory to such treatment. Such results underscore the surprising capacity of appropriately activated effector T cells to withstand the immunosuppressive, tolerogenic, and apoptotic influences of the typical tumor environment. Given the increasingly appreciated and critical communications between T cells and host Ag-presenting cells (APC), which cross-present tumor Ag, it is likely that dendritic cell-based vaccine maneuvers that promote sensitization of T1-committed L-selectin(low) antitumor T cells will play an increasingly important role in adoptive therapy strategies.


Subject(s)
Immunotherapy, Adoptive , Neoplasms/therapy , T-Lymphocytes/immunology , Animals , Antigen-Presenting Cells/immunology , Antigens, Neoplasm/analysis , Antigens, Neoplasm/immunology , Cell Communication , Cytokines/biosynthesis , Cytotoxicity, Immunologic , Histocompatibility Antigens Class I/analysis , Humans , Immune Tolerance , Killer Cells, Natural/immunology , Lymphocyte Activation , Models, Animal , Neoplasms/immunology
8.
Clin Cancer Res ; 7(10): 3276-81, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11595725

ABSTRACT

The antitumor effect of T cells is executed either through CD95 or Perforin (PFN)/Granzyme B (GrB) pathways. Induction of apoptosis by either mode requires activation of caspase family members. However, recent studies have suggested that cell death can proceed in the absence of caspase induction and apoptotic events. We investigated the contribution of CD95 and PFN/GrB-mediated cytotoxicity to apoptotic and necrotic mechanisms of cell death in human renal cell carcinoma. Although freshly isolated and cultured tumors expressed CD95 on their surface, they were resistant to CD95-mediated apoptosis. CD95 resistance coincided with decreased levels of FADD protein and diminished caspase-3-like activity. In contrast, we demonstrated that tumor cell death mediated by PFN/GrB can be achieved in the absence of functional caspase activity and is accompanied by a dramatic accumulation of nonapoptotic necrotic cells.


Subject(s)
Adaptor Proteins, Signal Transducing , Apoptosis/drug effects , Carcinoma, Renal Cell/pathology , T-Lymphocytes, Cytotoxic/immunology , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacology , Carcinoma, Renal Cell/immunology , Carcinoma, Renal Cell/metabolism , Carrier Proteins/metabolism , Caspase 8 , Caspase 9 , Caspases/metabolism , Drug Resistance, Neoplasm , Enzyme Activation/drug effects , Fas Ligand Protein , Fas-Associated Death Domain Protein , Granzymes , Humans , Jurkat Cells , Membrane Glycoproteins/metabolism , Membrane Glycoproteins/pharmacology , Necrosis , Perforin , Pore Forming Cytotoxic Proteins , Serine Endopeptidases/pharmacology , Tumor Cells, Cultured , fas Receptor/immunology , fas Receptor/metabolism
9.
Apoptosis ; 6(6): 419-29, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11595831

ABSTRACT

Alterations in intracellular Zn(2+) concentrations are believed to play a crucial role in modulating apoptosis. The observation that Zn(2+) deficiency can induce cell death both in vivo and in vitro has been attributed to the fact that exchange of Zn(2+) for Ca(2+) and Mg(2+) within the nuclei may directly activate endogenous endonucleases therefore inducing DNA fragmentation independent of cytoplasmic factors. Here we show that the membrane-permeable zinc chelator, N,N',N'-tetrakis(2-pyridylmethyl) ethylenediamine (TPEN) induces translocation of cytochrome c from the mitochondrial intramembranous space into the cytosol in human peripheral blood T lymphocytes (PBL) with subsequent activation of caspases-3, -8, and -9. Pretreatment of T lymphocytes with caspase inhibitors Z-VAD.fmk or DEVD.fmk prevented DNA fragmentation in response to TPEN indicating that apoptosis triggered by zinc deficiency is entirely dependent on activation of caspase family members. The release of cytochrome c and activation of downstream caspases precedes changes in the mitochondrial transmembrane potential (Delta Psim). Therefore, cytoplasmic and mitochondrial events are critical to this process.


Subject(s)
Apoptosis , T-Lymphocytes/pathology , Zinc/deficiency , Amino Acid Chloromethyl Ketones/pharmacology , Blotting, Western , Calcium/pharmacology , Caspase 3 , Caspase 8 , Caspase 9 , Caspases/metabolism , Cells, Cultured , Chelating Agents/pharmacology , Cytochrome c Group/metabolism , Cytoplasm/metabolism , DNA Fragmentation , Dose-Response Relationship, Drug , Electrophoresis, Polyacrylamide Gel , Enzyme Activation , Enzyme Inhibitors/pharmacology , Ethylenediamines/pharmacology , Flow Cytometry , Humans , Immunohistochemistry , Intracellular Membranes/metabolism , Jurkat Cells , Kinetics , Magnesium/pharmacology , Membrane Potentials , Mitochondria/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/metabolism , Time Factors , Zinc/metabolism , fas Receptor/biosynthesis
10.
Biochem Biophys Res Commun ; 287(4): 895-9, 2001 Oct 05.
Article in English | MEDLINE | ID: mdl-11573949

ABSTRACT

Nuclear factor kappaB (NFkappaB) regulates the expression of various genes essential for cell survival. Here we demonstrate that suppression of NFkappaB nuclear import with SN50 peptide carrying the nuclear localization sequence (NLS) of the NFkappaB p50 subunit induces apoptosis in human peripheral blood T lymphocytes (T-PBL), which can be blocked with the pan-caspase inhibitor Z-VAD.fmk. However, even when caspase function is blocked, the addition of SN50 induces irreversible cell loss due to the reduction in the mitochondrial transmembrane potential (DeltaPsim) followed by disruption of the cell membrane, hallmarks of necrosis. These observations demonstrate that although inhibition of NFkappaB nuclear translocation by SN50 peptide can induce caspase-dependent apoptosis in T-PBL, cell death may still proceed in the absence of functional caspase activity. The availability of downstream caspases appears to determine the mode of cell death in NFkappaB defective cells.


Subject(s)
Apoptosis/physiology , NF-kappa B/metabolism , T-Lymphocytes/physiology , Active Transport, Cell Nucleus/physiology , Amino Acid Chloromethyl Ketones/pharmacology , Caspase Inhibitors , Caspases/metabolism , Cell Nucleus/metabolism , Cells, Cultured , Cysteine Proteinase Inhibitors/pharmacology , DNA Fragmentation , Flow Cytometry , Humans , In Situ Nick-End Labeling , Membrane Potentials/physiology , Mitochondria/drug effects , Mitochondria/metabolism , NF-kappa B/antagonists & inhibitors , Peptides/metabolism , Peptides/pharmacology , T-Lymphocytes/drug effects
11.
Clin Cancer Res ; 7(3 Suppl): 940s-946s, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11300495

ABSTRACT

Antitumor immunity fails to adequately develop in many cancer patients, including those with renal cell carcinoma (RCC). A number of different mechanisms have been proposed to explain the immune dysfunction observed in cancer patient T cells. Here we show that T cells from RCC patients display increased sensitivity to apoptosis. Tumor-infiltrating lymphocytes (TILs) display the most profound sensitivity, because 10-15% of those cells are apoptotic when assessed by terminal deoxynucleotidyltransferase-mediated nick end labeling in situ, and the number of apoptotic TILs further increases after 24 h of culture. Peripheral blood T cells from RCC patients are not directly apoptotic, although T lymphocytes derived from 40% of those individuals undergo activation-induced cell death (AICD) upon in vitro stimulation with phorbol myristate acetate and ionomycin. This is in contrast to T cells from normal individuals, which are resistant to AICD. TILs and peripheral blood T cells from RCC patients also exhibit impaired activation of the transcription factor, nuclear factor (NF)-kappaB. Additional findings presented here indicate that the heightened sensitivity of patient T cells to apoptosis may be tumor induced, because supernatants from RCC explants sensitize, and in some instances directly induce, normal T cells to apoptosis. These same supernatants also inhibit NF-kappaB activation. RCC-derived gangliosides may represent one soluble tumor product capable of sensitizing T cells to apoptosis. Pretreatment with neuraminidase, but not proteinase K, abrogated the suppressive effects of tumor supernatants on both NF-kappaB activation and apoptosis. Additionally, gangliosides isolated from tumor supernatants not only inhibited NF-kappaB activation but also sensitized T cells to AICD. These findings demonstrate that tumor-derived soluble products, including gangliosides, may contribute to the immune dysfunction of T cells by altering their sensitivity to apoptosis.


Subject(s)
Apoptosis , Carcinoma, Renal Cell/immunology , Carcinoma, Renal Cell/pathology , Kidney Neoplasms/immunology , Kidney Neoplasms/pathology , NF-kappa B/physiology , Cell Nucleus/metabolism , DNA Fragmentation , Enzyme Activation , Gangliosides/metabolism , Humans , In Situ Nick-End Labeling , Ionomycin/pharmacology , Ionophores/pharmacology , Tetradecanoylphorbol Acetate , Time Factors
12.
Methods Mol Med ; 53: 361-76, 2001.
Article in English | MEDLINE | ID: mdl-21318807

ABSTRACT

Functional T cells are the central component of an effective antitumor immune response. However, in patients with renal cell carcinoma (RCC), the growth of antigenic tumors proceeds in the absence of significant T-cell responses, posing a distinct obstacle to the development of effective immunotherapy strategies and cancer vaccines. The minimum required elements of a functional antitumor immune T-cell response have been identified, including T cells that can preferentially recognize tumor-associated antigens (1). However, despite increasing evidence that T-cells recognize discrete tumor antigen, transformed cells continue to evade immune destruction, and tumors thereby progress. There is now little doubt that the immune response to tumor antigens is altered in patients with cancer (2). This rarely manifests clinically as generalized immune suppression, which may reflect the antigen specificity of the immune dysfunction in the initial stages of the disease.

13.
Cancer J Sci Am ; 6 Suppl 1: S81-7, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10685665

ABSTRACT

PURPOSE: The development of an effective antitumor immune response is compromised in patients with renal cell carcinoma. Despite significant infiltration by T lymphocytes into renal tumors, no detectable induction of gene expression is associated with the generation of an antitumor immune response. Tumor-induced down-regulation of interleukin (IL)-2 expression may contribute to the impaired development of the T cell-mediated antitumor immune response. Within renal tumors, there is no detectable expression of IL-2 or the IL-2 receptor alpha chain, and only low levels of interferon gamma (IFN-gamma) mRNA are detected. Products in the tumor environment may suppress the expression of these genes, thus inhibiting production of type 1 helper T cell cytokines. METHODS: Peripheral blood lymphocytes obtained from healthy volunteers were exposed to supernatants from renal cell carcinoma explants, and the immunologic consequences of this were assessed using a variety of molecular assays. RESULTS: Soluble products from renal tumor explants can inhibit the production of IL-2 and IFN-gamma by peripheral blood lymphocytes and can suppress T-cell proliferation. Soluble products from renal cell carcinoma explants appear to block the nuclear translocation of nuclear factor kappa B (NFkappaB) proteins p50 and RelA without affecting cytoplasmic levels of these proteins. In some experiments, a reduction in the nuclear translocation of other transcription factors involved in IL-2 gene expression, including nuclear factor of activated T cells and accessory protein-1, was observed. Gangliosides isolated from tumor supernatants blocked the production of IL-2 and IFN-gamma in response to ionomycin plus phorbol myristate acetate stimulation. These gangliosides also inhibited stimulus-dependent activation and nuclear accumulation of NFkappaB. Coculture experiments demonstrated that renal cell carcinoma lines known to express gangliosides could inhibit the activation of NFkappaB in normal T cells and the Jurkat T-cell line. Supernatants from renal cell carcinoma explants and renal cell carcinoma cell lines can also suppress the proliferation of normal T cells, thus reproducing another defect observed in tumor-infiltrating lymphocytes. Supernatants from renal cell carcinoma tumors also appear to inhibit signaling through the IL-2 receptor. Although tumor supernatants had little effect on IL-2 receptor (alpha, beta or gamma) expression, they did block expression of JAK3, a key kinase involved in signaling through the IL-2 receptor pathway. Moreover, downstream events in IL-2 receptor signaling linked to JAK3 were impaired in T cells treated with tumor supernatants. CONCLUSION: These findings suggest that soluble products from renal tumors may suppress T-cell responses by blocking both IL-2 production and normal IL-2 receptor signaling.


Subject(s)
Carcinoma, Renal Cell/immunology , Interleukin-2/biosynthesis , Kidney Neoplasms/immunology , Receptors, Interleukin-2/physiology , Humans , Interferon-gamma/biosynthesis , Lymphocyte Activation , NF-kappa B/metabolism , T-Lymphocytes/immunology , Tumor Cells, Cultured
14.
Apoptosis ; 5(1): 17-20, 2000 Feb.
Article in English | MEDLINE | ID: mdl-11227486

ABSTRACT

The majority of current anticancer therapies induce tumor cell death through the induction of apoptosis. Alterations in the apoptotic pathways may determine tumor resistance to these therapies. Activation of the proteolytic cascade involving caspase family members is a critical component of the execution of cell death in apoptotic cells. However, recent studies suggest that cell death can proceed in the absence of caspases. In this review we describe the role of caspase-dependent and -independent pathways as targets for anticancer treatment. A better understanding of diverse modes of tumor cell death will help to avoid ineffective treatment and provide a molecular basis for the new strategies targeting caspase-independent death pathways in apoptosis-resistant forms of cancer.


Subject(s)
Antineoplastic Agents/pharmacology , Caspases/metabolism , Cell Death , Neoplasms/drug therapy
15.
J Clin Invest ; 104(6): 769-76, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10491412

ABSTRACT

Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs.


Subject(s)
Carcinoma, Renal Cell/immunology , Gangliosides/pharmacology , I-kappa B Proteins , Immunosuppressive Agents/pharmacology , Kidney Neoplasms/immunology , NF-kappa B/antagonists & inhibitors , T-Lymphocytes/drug effects , DNA-Binding Proteins/metabolism , Humans , Interferon-gamma/biosynthesis , Interleukin-2/biosynthesis , NF-KappaB Inhibitor alpha , NF-kappa B/metabolism , T-Lymphocytes/metabolism
16.
Clin Cancer Res ; 5(5): 1219-29, 1999 May.
Article in English | MEDLINE | ID: mdl-10353760

ABSTRACT

Tumors may escape immune recognition and destruction through the induction of apoptosis in activated T lymphocytes. Results from several laboratories suggest that FasL (L/CD95L) expression in tumors may be responsible for this process. In this study of patients with renal cell carcinoma (RCC), we provide evidence for two mechanisms of T-cell apoptosis. One mechanism involves the induction of apoptosis via FasL expression in tumor cells. This is supported by several observations, including the fact that tumor cells in situ as well as cultured cell lines expressed FasL mRNA and protein by a variety of techniques. The FasL in RCC is functional because in coculture experiments, FasL+ tumors induced apoptosis in Fas-sensitive Jurkat T cells and in activated peripheral blood T cells but not in resting peripheral blood T cells. Most importantly, antibody to FasL partially blocked apoptosis of the activated T cells. Moreover, Fas was expressed by T cells derived from the peripheral blood (53% median) and tumor (44.3% median) of RCC patients. Finally, in situ staining for DNA breaks demonstrated apoptosis in a subset of T cells infiltrating renal tumors. These studies also identified a second mechanism of apoptosis in RCC patient peripheral T cells. Whereas these cells did not display DNA breaks when freshly isolated or after culture for 24 h in medium, peripheral blood T cells from RCC patients underwent activation-induced cell death after stimulation with either phorbol 12-myristate 13-acetate/ionomycin or anti-CD3/CD28 antibodies. Apoptosis mediated by exposure to FasL in tumor cells or through T-cell activation may contribute to the failure of RCC patients to develop an effective T-cell-mediated antitumor response.


Subject(s)
Apoptosis/physiology , Carcinoma, Renal Cell/immunology , Kidney Neoplasms/immunology , Lymphocytes, Tumor-Infiltrating/cytology , Membrane Glycoproteins/physiology , Neoplasm Proteins/physiology , T-Lymphocytes, Cytotoxic/cytology , Apoptosis/drug effects , Blood Cells/immunology , Carcinoma, Renal Cell/blood , DNA Fragmentation , Fas Ligand Protein , Humans , In Situ Nick-End Labeling , Ionomycin/pharmacology , Jurkat Cells/immunology , Kidney Neoplasms/blood , Lymphocyte Activation , Lymphocytes, Tumor-Infiltrating/immunology , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/genetics , Muromonab-CD3/pharmacology , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Polymerase Chain Reaction , RNA, Messenger/biosynthesis , RNA, Neoplasm/biosynthesis , T-Lymphocytes, Cytotoxic/immunology , Tetradecanoylphorbol Acetate/pharmacology , Tumor Cells, Cultured , fas Receptor/physiology
17.
Cancer Res ; 59(12): 2838-42, 1999 Jun 15.
Article in English | MEDLINE | ID: mdl-10383143

ABSTRACT

The antitumor effect of immuno- and chemotherapeutic agents is executed through stimulation of apoptotic programs in susceptible cells. Apoptosis induced in tumor cells requires activation of members of the caspase family of proteases. Deficient expression or activation of caspases may account in part for the failure of many current anticancer therapies. However, recent studies suggest that cell death can proceed in the absence of caspases. We investigated the susceptibility of human renal cell carcinoma (RCC) lines to two distinct modes of cell death, apoptosis and necrosis. RCC lines displayed almost complete resistance to apoptosis in response to the intracellular zinc chelator, N,N,N'N'-tetrakis (2-pyridylmethyl) ethylenediamine (TPEN), which instead induced dramatic accumulation of nonapoptotic necrotic cells. Conversely, TPEN was a potent inducer of apoptosis in caspase-competent normal kidney cells (NK-72) and Jurkat T lymphocytes. Resistance to apoptosis in RCC lines correlated with almost complete loss of caspase-3 expression and variable down-regulation of caspase-7, caspase-8, and caspase-10. These data may explain the resistance of RCC to drugs inducing apoptosis and have important consequences for further attempts to manipulate tumor cell death.


Subject(s)
Carcinoma, Renal Cell/pathology , Caspases/metabolism , Kidney Neoplasms/pathology , Apoptosis , Carcinoma, Renal Cell/enzymology , Caspases/deficiency , Cholinesterase Inhibitors/pharmacology , Ethylenediamines/pharmacology , Humans , Jurkat Cells , Kidney Neoplasms/enzymology , Killer Cells, Natural/drug effects , Killer Cells, Natural/pathology , Necrosis , T-Lymphocytes/drug effects , T-Lymphocytes/pathology , Tumor Cells, Cultured
19.
J Immunother ; 22(1): 71-9, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9924702

ABSTRACT

Interleukin-12 (IL-12) is a heterodimeric cytokine that enhances the cytolytic activity, proliferation, and interferon-gamma (IFN-gamma) production by T lymphocytes and natural killer cells, and has significant antitumor activity in a variety of murine tumor models. The induction of interferon (IFN)-gamma by IL-12 in tumor-bearing mice plays an important role in its antitumor activity. We therefore examined the effects of IL-12 on IFN-gamma production by T cells derived from patients with renal cell carcinoma (RCC), including freshly isolated tumor infiltrating lymphocytes (T-TIL), matched peripheral blood T cells (T-PBL), and RCC-specific TIL lines. IL-12 alone induced IFN-gamma secretion by T cells from normal individuals and appeared to act synergistically with either IL-2 or anti-CD3 antibody. In contrast, it failed to stimulate significant IFN-gamma secretion by T-PBL and T-TIL from RCC patients. This unresponsive state in T-PBL appeared selective because IFN-gamma was produced when cells were stimulated with either phytohemagglutinin or anti-CD3 antibody. Moreover, costimulation through the T-cell receptor (TCR)/CD3 complex or with IL-2 made T-PBL from RCC patients responsive to IL-12, possibly secondary to the upregulation of IL-12R (beta chain). A selective loss of IL-12-dependent production of IFN-gamma was also consistently observed in two of three established RCC-specific TIL lines. Although these cell lines did not respond to any concentration of IL-12, they did produce IFN-gamma after ligation of the TCR/CD3 or stimulation with IL-2, IL-12 also acted either syngeristically or additively with IL-2, anti-CD3 antibody, or autologous tumor cells to induce IFN-gamma production. The observed decreases in IFN-gamma production in response to IL-12 may have a negative effect on the development of T-cell immunity. The clinical importance of these findings during in vivo administration of IL-12 remains to be determined.


Subject(s)
Carcinoma, Renal Cell/immunology , Interferon-gamma/biosynthesis , Interleukin-12/pharmacology , Kidney Neoplasms/immunology , Lymphocytes, Tumor-Infiltrating/immunology , T-Lymphocytes/immunology , Carcinoma, Renal Cell/drug therapy , Cell Separation , DNA/biosynthesis , Flow Cytometry , Humans , Interleukin-2/pharmacology , Kidney Neoplasms/drug therapy , Lymphocyte Activation/drug effects , Lymphocytes, Tumor-Infiltrating/drug effects , Muromonab-CD3/immunology , Phytohemagglutinins/pharmacology , Receptors, Interleukin/metabolism , Receptors, Interleukin-12 , Recombinant Proteins/pharmacology , T-Lymphocytes/drug effects , Tumor Cells, Cultured
20.
Clin Cancer Res ; 4(10): 2337-47, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9796963

ABSTRACT

Studies have demonstrated abnormalities of the CD3/T-cell antigen receptor (TCR) and pathways of signal transduction in T lymphocytes from animals and patients with advanced malignancy. Diminished expression of TCRzeta and p56(lck) that are associated with the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted. These defects have been described in T cells from patients with malignant melanoma, renal cell carcinoma (RCC), ovarian cancer, and colorectal cancer. Preliminary observations also indicate possible correlation with clinical variables such as stage in selected instances. To further characterize altered expression of TCRzeta, p56(lck), and impaired activation of NFkappaB, T lymphocytes were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals. In 29 of these patients, levels of TCRzeta and p56(lck) were determined by Western blots of T-cell lysates and semiquantitated using densitometry. Relative levels were then correlated with a series of clinical variables including response to therapy, performance status, survival, disease sites, age, and others. In another group of 28 patients (three individuals from the first group), the frequency of abnormal NFkappaB activation was studied using electrophoretic mobility shift assays after activation of T cells with phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody. Changes in these signaling molecules during cytokine treatment were also investigated. TCRzeta and p56(lck) were detected in the peripheral blood T cells in 27 of 29 patients, and overall, reduced levels were noted visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively. When levels were semiquantitated using densitometry, significant decreases of TCRzeta (P = 0.029) and p56(lck) (P = 0.029) but not CD3epsilon (P = 0.131), compared with control levels, were found. In patients treated with IL-2/IFN alpha-based therapy, relative levels of TCRzeta increased significantly (P = 0.002) on day 15 of cycle one compared with the baseline. Correlations of TCRzeta or p56(lck) levels with response or disease variables, except for lower TCRzeta levels (P < 0.001) in the presence of bone metastases, were not found. Abnormal NFkappaB activation after stimulation with phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort. Activation of NFkappaB in peripheral blood T cells was inducible during cytokine therapy in four of six individuals who displayed impaired NFkappaB activity prior to therapy. Moreover, impaired activation of NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible. In the majority of patients with advanced RCC, peripheral blood T cells express TCRzeta and p56(lck), and in a subset, reduced levels of these TCRzeta associated molecules are seen that may increase during cytokine-based therapy. Abnormal activation of NFkappaB is also present in >50% of patients and may also revert to normal during IL-2/IFN alpha-based treatment. This alteration in NFkappaB activation occurred in the presence of normal expression of TCRzeta-associated signaling elements. The clinical significance of these findings remains unclear.


Subject(s)
Carcinoma, Renal Cell/immunology , Cytokines/therapeutic use , Kidney Neoplasms/immunology , Signal Transduction , T-Lymphocytes/metabolism , Carcinoma, Renal Cell/therapy , Humans , Kidney Neoplasms/therapy , Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/analysis , Membrane Proteins/analysis , NF-kappa B/metabolism , Receptors, Antigen, T-Cell/analysis
SELECTION OF CITATIONS
SEARCH DETAIL